Litigation Details for Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2025)

Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2025)

Docket	1:25-cv-01539	Date Filed	2025-12-19
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Patents	10,512,657; 11,229,647; 11,229,661; 11,260,053; 11,376,251; 11,497,745; 11,918,578; 12,350,267
Attorneys	Nathan Roger Hoeschen
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-12-19				External link to document

Mirum Pharmaceuticals v. Zenara Pharma (D.N.J. 1:25-cv-01539): Litigation Summary, Claims at Stake, and Early Risk Assessment

Last updated: June 3, 2026

Mirum Pharmaceuticals, Inc. has sued Zenara Pharma Private Limited in the US District Court for the District of New Jersey under docket 1:25-cv-01539. The case name indicates a patent-infringement posture typical of FDA Orange Book-driven disputes (often filed in parallel with Paragraph IV litigation). This creates a near-term pathway to an injunction request, a launch/skinny label dispute, and a stayed litigation posture depending on FDA timing and Hatch-Waxman procedure.

What is Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited, 1:25-cv-01539 about?

Answer: The docket 1:25-cv-01539 is a federal patent litigation brought by Mirum Pharmaceuticals, Inc. against Zenara Pharma Private Limited in D.N.J. The specific asserted patents, product designation, and claim theories are not contained in the provided prompt text. Without the complaint, patent list, ANDA/BLA number, or FDA submission details, a precise claim-by-claim map cannot be produced.

What court and procedural posture does the docket imply?

The format “1:25-cv-01539” corresponds to a district-court civil action filed in 2025. In Mirum-linked patent cases, the usual pattern is:

• One or more asserted Orange Book patents listed for the reference listed drug (RLD)
• Relief seeking a court finding of non-infringement and/or invalidity by the ANDA/BLA filer, or a finding of infringement by the patent owner
• Potential request for injunctive relief to prevent launch during the pendency of the case

Key litigation documents that drive the analysis

A litigation summary that supports licensing, design-around, or generic-launch risk must anchor to:

• The Complaint (asserted patents, product, counts)
• The Answer and Invalidity defenses (anticipation, obviousness, lack of written description, prosecution history estoppel, improper inventorship)
• Any motion practice (TRO/preliminary injunction, dismissal under Rule 12(b), claim construction)
• The Markman schedule if claim construction is reached
• The case management order setting deadlines for expert work and trial

No such document text or metadata is provided in the prompt.

Which patents are asserted in Mirum v. Zenara Pharma (1:25-cv-01539)?

Answer: Not specified in the provided material. A patent estate analysis requires the asserted patent numbers, assignees, expiration dates, and whether they are composition, formulation, method-of-use, or manufacturing patents.

How to structure the patent estate analysis once asserted patents are known

For business decisions, the patent estate summary should include, for each asserted patent:

• Patent number, title, assignee, priority date
• Claimed subject matter (composition vs formulation vs method-of-use)
• Expiration and any terminal disclaimers
• Claim chart inputs (independent claims at issue)
• Expected defenses:
  • Non-infringement of formulation limits or dose regimen
  • Obviousness vs prior art dosage/formulation
  • Indefiniteness or lack of enablement
  • For method-of-use: induced infringement and carveouts

Is this a Paragraph IV or other FDA-related Hatch-Waxman dispute?

Answer: The prompt does not include the FDA pathway (ANDA/BLA), submission type, or any indication of Paragraph IV. The docket title alone is not sufficient to determine whether this is an ANDA Paragraph IV litigation, a follow-on biologic dispute, or another patent remedy.

How the FDA pathway changes outcomes and timelines

• ANDA Paragraph IV (typical Orange Book): creates statutory decision timing, potential 30-month stay, and automatic procedural hooks (answers, amendments, notice of certifications).
• Non-Paragraph IV: can lead to faster or slower injunction posture depending on the regulatory posture and whether the filer seeks a section-specific approval.
• Biosimilar-related: uses different statutory scheme and evidence benchmarks.

Without the submission type, any timeline statement would be speculative.

What relief is Mirum seeking against Zenara in 1:25-cv-01539?

Answer: The prompt does not provide the complaint’s requested relief. In these disputes, typical requested relief includes:

• Declaration of infringement
• Injunction preventing FDA approval and/or commercial launch
• Attorney’s fees (under 35 U.S.C. § 285) if asserted standards are met
• Costs

A precise listing requires the complaint’s “Prayer for Relief” section.

What does the early litigation posture suggest for settlement versus trial?

Answer: Not determinable from the prompt. In high-probability Orange Book disputes, parties frequently negotiate a settlement that:

• Allocates a design-around or carveout
• Sets an entry date and permitted launch geography
• Defines “at-risk” launch consequences if a settlement term is breached

But predicting settlement terms or probability requires:

• The asserted patent strength and remaining life
• Any existing collaboration or licensing history
• The parties’ litigation schedules and motions

None of these inputs are provided.

How strong is Mirum’s patent estate for the product likely at issue?

Answer: Not computable from the provided prompt. Patent strength analysis requires:

• The asserted claim set
• Known prior art landscape
• Prior claim construction, injunction rulings, or PTAB outcomes
• Remaining patent term and any exclusivity interplay (data exclusivity, market exclusivity)

What “strength” usually depends on in Mirum-style cases

When the asserted patents are formulation or method-of-use, non-infringement often turns on:

• Exact composition ranges (active amount, excipients, particle size, stabilizers)
• Intended use dosing regimen and labeling
• Whether the accused product’s instructions induce or contribute to infringement

In contrast, composition claims can be more resilient against simple manufacturing swaps.

When does the asserted patent family lose exclusivity or expire?

Answer: Not specified. Patent expiration and regulatory exclusivity are central to launch-risk calendars, but no asserted patent numbers or FDA exclusivity data is included in the prompt.

What a working exclusivity calendar must include

A decision-grade timeline typically layers:

• Patent expiration (with any PTA and terminal disclaimer impact)
• Periodic maintenance fee status
• Patent term adjustment (PTA) and any reexamination/extension
• FDA statutory exclusivity (data exclusivity, pediatric exclusivity) if applicable
• Any settlement entry date if a consent judgment exists

What generic entry risks exist for Zenara or other challengers?

Answer: Not quantifiable from the prompt. At minimum, entry risk depends on:

• Whether Zenara’s regulatory submission is blocked by an injunction
• Whether a 30-month stay applies and whether it has lapsed
• The scope of the court’s remedies if infringement is found

At-risk launch triggers that drive exposure

Key triggers:

• Court denial of a motion to stay or preliminary injunction grant timing
• Claim construction outcomes narrowing the asserted claims
• Final judgment schedule versus FDA approval timing

No schedule or rulings are provided.

How does Zenara’s risk profile compare with other Mirum challengers?

Answer: Not possible with the given prompt. A comparative analysis requires the list of:

• Other defendants in Mirum’s Orange Book litigation
• Their asserted patent charts
• Whether they have settled, lost, or are pending at similar procedural stages

What is the Orange Book status of the Mirum product at issue?

Answer: Not provided. Orange Book status analysis must include:

• RLD name(s)
• Listed patents for the RLD
• Patent types and dates
• Certification types for the challenger submission

Without the RLD name or asserted patent numbers, no Orange Book mapping can be produced.

Litigation timeline: what deadlines and events matter in 1:25-cv-01539?

Answer: No docket entry dates or case schedule are provided in the prompt, so a timeline cannot be built.

What a complete timeline must record

For actionable litigation management, the timeline should capture:

• Complaint filing date
• Service date
• Defendant response deadline and filing date of answer
• Any amendments to infringement contentions
• Markman scheduling order
• Motion dates for:
  • preliminary injunction
  • stay pending PTO/ITC proceedings (if any)
  • summary judgment
• Trial date or dispositive motion schedule
• Status of appeal if any

None of these are included.

Key takeaways

• The docket Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (1:25-cv-01539, D.N.J.) is confirmed as an ongoing federal litigation posture, but the prompt provides no asserted-patent list, FDA submission details, or procedural events.
• A business-grade litigation summary that supports freedom-to-operate, launch planning, or licensing strategy cannot be completed without the complaint-derived patent and product specifics.

FAQs

1. What is the case status of Mirum Pharmaceuticals v. Zenara Pharma (1:25-cv-01539)?
2. Which patents does Mirum assert against Zenara in D.N.J. 1:25-cv-01539?
3. Is Zenara’s FDA submission a Paragraph IV ANDA or another pathway in this case?
4. What claims are typically asserted in Mirum Orange Book patent litigations and how do defendants defend them?
5. How do settlement terms in Mirum-style Hatch-Waxman cases usually impact launch timing and design-around options?

References (APA)

1. Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited, No. 1:25-cv-01539 (D.N.J. filed 2025).